• Popular
    • Medicine
    • Radiology
    • Cardiology
    • Surgery
    • Nanomedicine
    • Military Medicine
    • Rehab
  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS
  • Submit PR
  • Log in
Medgadget
Medgadget
  • Popular
    • Medicine
      Flexible Sensors Detect Heavy Metals in Sweat

      Flexible Sensors Detect Heavy Metals in Sweat

      Nanopore Sensor to Study Protein Aggregation in Neurodegeneration

      Nanopore Sensor to Study Protein Aggregation in Neurodegeneration

      Biobots Use Optogenetic Muscle Actuators for Movement

      Biobots Use Optogenetic Muscle Actuators for Movement

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

    • Radiology
      Ultrasound Tornado Rapidly Disrupts Blood Clots

      Ultrasound Tornado Rapidly Disrupts Blood Clots

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

      Fluorescence Imaging System Illuminates Tumor Depth

      Fluorescence Imaging System Illuminates Tumor Depth

      Soft Robot Grows Like a Plant to Travel Through Tight Spaces

      Soft Robot Grows Like a Plant to Travel Through Tight Spaces

    • Cardiology
      Belt Monitors Heart Failure Patients

      Belt Monitors Heart Failure Patients

      Camera Measures Blood Pressure with Quick Look

      Camera Measures Blood Pressure with Quick Look

      Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

      Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

    • Surgery
      Microneedle Bandage for Hemostatic Control

      Microneedle Bandage for Hemostatic Control

      Biobots Use Optogenetic Muscle Actuators for Movement

      Biobots Use Optogenetic Muscle Actuators for Movement

      Implantable Device Adheres to Muscle, Treats Atrophy

      Implantable Device Adheres to Muscle, Treats Atrophy

      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

    • Nanomedicine
      Extra Hot Nanoparticles for Cancer Therapy

      Extra Hot Nanoparticles for Cancer Therapy

      Making Tumors Tastier for the Immune System

      Making Tumors Tastier for the Immune System

      Improved Membrane Coating for Anti-Cancer Nanoparticles

      Improved Membrane Coating for Anti-Cancer Nanoparticles

      Magnetic Bacteria Target Tumors

      Magnetic Bacteria Target Tumors

    • Military Medicine
      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fabric Makes Electricity from Movement to Power Wearables

      Fabric Makes Electricity from Movement to Power Wearables

      Wearable Uses Microneedles to Track Metabolism

      Wearable Uses Microneedles to Track Metabolism

    • Rehab
      Smart Walking Stick for Visually Impaired People

      Smart Walking Stick for Visually Impaired People

      Implantable Device Adheres to Muscle, Treats Atrophy

      Implantable Device Adheres to Muscle, Treats Atrophy

      Non-Invasive Spinal Modulation for Cerebral Palsy

      Non-Invasive Spinal Modulation for Cerebral Palsy

      Implanted Magnets for Prosthetic Control

      Implanted Magnets for Prosthetic Control

  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Log in
  • Submit PR
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS

Early Success in HVAD LATERAL Trial: Interview with Medtronic’s Dr. David Steinhaus, M.D., Vice President and General Manager, Heart Failure

April 19th, 2017 Conn Hastings Cardiac Surgery, Cardiology, Exclusive

Medtronic recently announced the early success of the HVAD LATERAL trial. The trial is investigating the potential to implant Medtronic’s HVAD device via a less invasive lateral thoracotomy, instead of the more conventional median sternotomy. The HVAD is a ventricular assist device, consisting of a mechanical pump attached to the heart, that assists in pumping blood around the body in patients with heart failure. In the United States, the device is implanted using a median sternotomy, where the sternum is parted and the chest opened. This latest trial investigates placing the device through a lateral thoracotomy, in which a small incision between the ribs is used to access the heart. The idea is that a thoracotomy is much less invasive than a median sternotomy, and the recovery time should be less. The device is already approved in Europe for surgical placement through a thoracotomy.

Medgadget asked David Steinhaus, M.D., vice president and general manager of the Heart Failure business at Medtronic, some questions about the technology and the ongoing trial.

 

Conn Hastings, Medgadget: Please give us a brief overview of the HVAD and the type of patient who is eligible for treatment with an HVAD.

David Steinhaus: The HeartWare centrifugal-flow, ventricular assist device (HVAD) is a mechanical pump that attaches directly to the heart and circulates oxygen-rich blood throughout the body in patients with advanced heart failure. The HVAD System consists of a pump, an external controller, a connecting cable and power sources that run the pump and controller. The HVAD has been proven to extend life, augment cardiac function and improve quality of life for end-stage heart failure patients, and the HVAD system is approved as a bridge to transplant in the U.S.

 

Medgadget: Can you explain the advantages of thoracotomy as opposed to median sternotomy in terms of patient morbidity and recovery time?

David Steinhaus: A thoracotomy is a small, lateral surgical incision between the patient’s ribs on the left side of the chest, whereas the more commonly used median sternotomy is a surgical procedure in which a vertical incision is made down the middle of the chest, then the sternum is divided. The thoracotomy technique is less invasive and preserves the chest for a possible subsequent sternotomy, such as that occurring at the time of heart transplantation. Additionally, the thoracotomy technique may provide patient benefits such as less tissue trauma and shorter hospital stays.

 

Medgadget: Is a thoracotomy more challenging for the surgeon, in terms of limited space to operate? Is the HVAD well-suited to delivery via thoracotomy?

David Steinhaus: In Europe, the HVAD System is the only full-support, centrifugal LVAD approved for implantation via the thoracotomy procedure, in addition to a median sternotomy procedure. The thoracotomy option is possible because of its smaller size relative to other LVADs on the market. But in the U.S., this implant technique is not approved by the FDA for any LVADs.

 

Medgadget: The trial has successfully met its primary endpoint. Can you summarize these early results and explain their significance?

David Steinhaus: The LATERAL trial sought to evaluate the thoracotomy implant technique of the HeartWare HVAD System in patients with advanced heart failure who are eligible for heart transplant. It is a multicenter, prospective, controlled clinical trial of 145 patients with end-stage heart failure who have not responded to medical management.

LATERAL successfully met its primary endpoint, with 87.6 percent of patients alive on the original device, free from disabling stroke, or having been explanted due to recovery at six months. This is compared to the performance goal of 77.5 percent, so you can see the study succeeded, and even surpassed its target (p-value=0.002). Overall survival among patients receiving an HVAD via the thoracotomy procedure was 91.8 percent at six months.

LATERAL validates that HVAD implantation via a thoracotomy is a viable alternative to median sternotomy. FDA approval of this investigational approach could ultimately result in more flexibility in implant planning and changes to patient management and recovery.

 

Medgadget: If it can be shown that delivery of HVAD through a thoracotomy produces similar or better therapeutic outcomes than delivery with median sternotomy, do you envisage this being the sole delivery method for the device globally?

David Steinhaus: There is a growing trend toward the use of less-invasive approaches in all fields of cardiac surgery. The positive results of the LATERAL trial show that the less-invasive thoracotomy procedure for implanting the HVAD System is feasible.

A sternotomy leads to adhesions and scar tissue, which are much more difficult to work through in a subsequent sternotomy, particularly at the time of a heart transplant. Of course, physician preference for implant technique certainly comes into play, but what we are seeing in Europe – where the thoracotomy approach for the HVAD is already approved – is the smaller size of the HVAD System makes it suitable for either implant approach. The thoracotomy option is not seen by physicians as feasible with the larger LVAD pumps.

 

Medgadget: The ENDURANCE trial is examining the potential of the HVAD system as a long-term therapy for heart failure patients, as opposed to a stop-gap treatment until heart transplant can occur. Recently, a subset of data showing that sicker patients in the trial did not have worse outcomes than less sick patients has been presented at the International Society for Heart and Lung Transplantation Scientific Meeting in San Diego. Can you comment on the significance of these results?

David Steinhaus: This was an interesting finding from the original ENDURANCE trial – that sicker patients didn’t necessarily have worse outcomes, which is contrary to some of the other published literature.

But a bigger splash at the ISHLT was from the ENDURANCE Supplemental trial, which was one of the other late breakers. You may remember that the original ENDURANCE trial demonstrated the safety and efficacy of the HVAD System for destination – or long-term – therapy; those results were presented at this meeting two years ago. But we saw a higher stroke rate than anticipated, so this second trial included intentional blood pressure management of HVAD patients in an effort to bring down the stroke rate – which it did. In fact, one of the prespecified secondary endpoints showed that the HVAD was superior to the control device in terms of being alive on the originally implanted device and free of disabling stroke – which is the endpoint of most LVAD therapy clinical trials. As you may imagine, these results were very well received by the physician community.

Flashback: Interview with David Steinhaus, VP of Cardiac Rhythm Disease Management at Medtronic…

Conn Hastings

Conn Hastings received a PhD from the Royal College of Surgeons in Ireland for his work in drug delivery, investigating the potential of injectable hydrogels to deliver cells, drugs and nanoparticles in the treatment of cancer and cardiovascular diseases. After achieving his PhD and completing a year of postdoctoral research, Conn pursued a career in academic publishing, before becoming a full-time science writer and editor, combining his experience within the biomedical sciences with his passion for written communication.

Sponsored
C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

New Clarius Power Fan HD3 Delivers a First for Handheld Ultrasound: Continuous Scanning

New Clarius Power Fan HD3 Delivers a First for Handheld Ultrasound: Continuous Scanning

Fluidx Unveils New Embolic for Neurovascular Use

Fluidx Unveils New Embolic for Neurovascular Use

Annalise.ai and Nuance Communications (a Microsoft Company) Announce Key Partnership to Improve Patient Outcomes with Workflow-Integrated AI

Annalise.ai and Nuance Communications (a Microsoft Company) Announce Key Partnership to Improve Patient Outcomes with Workflow-Integrated AI

PT Genie Unveils New Brand Identity Reflecting Company’s Transformation and Focus on the Global Future of AI and Machine Learning in Digital Healthcare

interviews & reviews
Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

Exciting Medtech at the Healthcareᐩ Expo Taiwan

Exciting Medtech at the Healthcareᐩ Expo Taiwan

Medgadget Visits Healthcareᐩ Expo Taiwan

Medgadget Visits Healthcareᐩ Expo Taiwan

Diabetes Management Tech for Type II patients: Interview with Jeffrey Brewer, CEO of Bigfoot Biomedical

Diabetes Management Tech for Type II patients: Interview with Jeffrey Brewer, CEO of Bigfoot Biomedical

Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

In-Office Pediatric Ear Tube Procedures: Interview with Preceptis Medical's Greg Mielke

In-Office Pediatric Ear Tube Procedures: Interview with Preceptis Medical's Greg Mielke

Symani Microsurgical Robotic System: Interview with Mark Toland, CEO of Medical Microinstruments

Symani Microsurgical Robotic System: Interview with Mark Toland, CEO of Medical Microinstruments

  • Subscribe
  • Contact us
  • Submit
  • About
  • Back to top
Medgadget

Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.

  • About
  • Editorial policies
  • Contact
  • Terms of Service
  • Privacy
  • Submit press release
  • Advertise
© Medgadget, Inc. All rights reserved. | The Medical Revolution Will Be Blogged.
Please support this website by adding us to your whitelist in your ad blocker. Ads are what helps us bring you premium content! Thank you!
Posting....
  • Facebook
  • Twitter
  • LinkedIn
  • Reddit
  • Email